Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 72Thoracic 1Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × apalutamide × Thoracic × Clear all
NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
2 enrolled 12 charts
GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡